Skip to main content

01.03.2013 | Original Paper | Ausgabe 1/2013

Medical Oncology 1/2013

Clinical outcomes of atypical carcinoid tumors of the lung and thymus: 7-year experience of a rare malignancy at single institute

Medical Oncology > Ausgabe 1/2013
Boram Han, Jong-Mu Sun, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn


Atypical carcinoid tumors above the diaphragm are extremely rare and are associated with unfavorable clinical outcomes compared to typical carcinoid tumors. We described various clinical and histological features and investigated outcomes in patients with atypical carcinoid tumor of the lung and thymus. Medical records were reviewed in patients diagnosed with atypical carcinoid tumor of the lung or thymus at Samsung Medical Center between December 2003 and April 2010. We reviewed patient characteristics and treatment modalities and analyzed patient outcome in terms of disease-free survival and overall survival. Of the nineteen study patients, there were twelve patients with atypical carcinoid tumors of the lung and seven patients with thymic ones. All patients except one underwent complete resection as the main treatment. All patients who had tumors with lesser mitoses (≤5/10 high-power fields) are presently alive; moreover, they are all free of recurrence except for one patient who is also alive with recurrent tumor without any palliative treatment. Distant metastasis after curative resection developed in six patients and two of them died of progressive disease 25–31 months after recurrence even after palliative systemic chemotherapy. Atypical carcinoid tumor of the lung and thymus was a malignant disease that was prone to metastasize to distant sites even after curative resection and adjuvant treatment. Number of mitosis was a predicting factor for recurrence of disease and death in patients with atypical carcinoid tumor of the lung and thymus.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf

Weitere Produktempfehlungen anzeigen
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2013

Medical Oncology 1/2013 Zur Ausgabe
  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.